- Home
- KNF vs APLS Comparison
KNF vs APLS Comparison
Compare KNF & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNF | APLS |
|---|---|---|
| Founded | 1917 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.2B |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KNF | APLS |
|---|---|---|
| Price | $87.56 | $40.91 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 21 |
| Target Price | ★ $97.25 | $33.59 |
| AVG Volume (30 Days) | 483.7K | ★ 8.7M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | ★ 2.76 | 0.20 |
| Revenue | ★ $3,146,012,000.00 | $1,003,782,000.00 |
| Revenue This Year | $9.38 | N/A |
| Revenue Next Year | $5.49 | $18.19 |
| P/E Ratio | ★ $32.19 | $204.63 |
| Revenue Growth | 8.52 | ★ 28.46 |
| 52 Week Low | $58.72 | $16.10 |
| 52 Week High | $101.02 | $40.95 |
Technical Indicators
Market Signals| Indicator | KNF | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.57 | 87.39 |
| Support Level | $75.76 | $19.29 |
| Resistance Level | $92.91 | N/A |
| Average True Range (ATR) | 3.65 | 0.12 |
| MACD | 0.69 | -0.18 |
| Stochastic Oscillator | 82.40 | 92.50 |
Price Performance
Historical ComparisonAbout KNF Knife Riv Holding Co.
Knife River Holding Co is an aggregates-led construction materials and contracting services provider. The segments of the company include West, Mountain, Central, and Energy Services. Each geographic segment offers a vertically integrated suite of products and services, including aggregates, ready-mix concrete, asphalt, and contracting services, while the Energy Services segment, which has locations throughout the company's geographic footprint, produces and supplies liquid asphalt and related services, for use in asphalt road construction, and is a supplier to some of the other segments.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).